Exact Sciences Corp

EXAS

103.180USD

+0.520+0.51%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Exact Sciences Corp's Score

Industry at a Glance

Industry Ranking

72 / 392

Overall Ranking

192 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Exact Sciences Corp Highlights

StrengthsRisks

Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 32.37% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 2.76B.

Fairly Valued

The company’s latest PE is -19.32, at a medium 3-year percentile range.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 2.35K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.52.

Analyst Rating

Based on 23 analysts

Hold

Current Rating

101.833

Target Price

-0.81%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Exact Sciences Corp is 7.31, ranking 122 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 850.74M, representing a year-over-year increase of 20.05%, while its net profit experienced a year-over-year increase of 48.76%.

Score

Industry at a Glance

Previous score

7.31

Change

0



Financials

6.71

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

2.69

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.64

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.52

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Exact Sciences Corp is 7.55, ranking 102 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -19.32, which is -62.23% below the recent high of -7.30 and -283.54% above the recent low of -74.11.

Score

Industry at a Glance

Previous score

7.55

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 72/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Exact Sciences Corp is 6.26, ranking 338 out of 392 in the Biotechnology & Medical Research industry. The average price target is 105.00, with a high of 105.00 and a low of 68.11.

Score

Industry at a Glance

Previous score

6.26

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Exact Sciences Corp is 5.74, ranking 297 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 103.79 and the support level at 102.20, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.18

Change

0.56

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Exact Sciences Corp is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 105.49%, representing a quarter-over-quarter decrease of 0.60%. The largest institutional shareholder is The Vanguard, holding a total of 17.37M shares, representing 9.10% of shares outstanding, with 2.23% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

17.76M

-0.57%

Capital World Investors

16.14M

-11.31%

Fidelity Management & Research Company LLC

15.38M

-33.94%

BlackRock Institutional Trust Company, N.A.

7.15M

+1.66%

Wellington Management Company, LLP

5.33M

-55.63%

State Street Investment Management (US)

5.20M

-3.42%

Citadel Advisors LLC

3.94M

+805.07%

Columbia Threadneedle Investments (US)

3.73M

+899.61%

Geode Capital Management, L.L.C.

3.31M

+2.31%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Exact Sciences Corp is 6.44, ranking 26 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.42. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Exact Sciences Corp

EXAS

7.00 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment